A public health worker I know sent me a photo last week. It showed two syringes, one with a clean white barrel, the other stamped with a bright orange logo and a brand name. “Why do people I work with keep asking for the orange ones?” she asked. She wasn’t just curious; she was unsettled. She runs a needle exchange program, and she’d noticed that some clients would refuse a syringe unless it was from a specific manufacturer. It was a pattern, not an isolated preference. Her question stayed with me, partly because it sounded like something out of a marketing textbook, not a clinic. Was syringe branding actually shaping health decisions? The evidence, it turns out, is stronger than most of us in public health have acknowledged.
A recent qualitative study set out to map exactly how syringe manufacturers use branding, and what that means for the millions of people who inject drugs globally. The researchers analyzed a broad sample of insulin and tuberculin syringes sold around the world. They catalogued logos, color schemes, brand names, and symbols stamped onto the barrels and packaging. Then they interviewed people who inject drugs to understand how these visual cues played into their decisions. The findings point to a quiet but pervasive force that many harm reduction strategies overlook.
The Visual Language of a Syringe
Walk into any pharmacy and glance at the syringe shelf. You’ll spot the green cross of a BD needle, the crimson emblem of a Terumo, the clean sans-serif font of a lesser-known brand. These aren’t accidental. Manufacturers invest thought into making their products recognizable, sometimes with the same care a soda company puts into its label. The study identified that colors, logos, and text are used to communicate reliability, sharpness, and even a sense of safety. A red logo might be read as strength. A simple sans-serif font can signal modernity. For a product that carries profound health implications, these design choices operate beneath the radar of most clinicians and policymakers.
Branding in syringes emerged primarily from the medical market. Manufacturers developed distinct identities to compete among hospitals and pharmacies, never intending to influence people who inject drugs outside clinical settings. Yet because insulin and tuberculin syringes—small, fine-gauge, and widely available—are favored by many people who inject, the branding crossed over into an entirely different context. A diabetic’s trust in a brand becomes a street-level reputation.
What the Research Uncovered
The study, published in Drugs: Education, Prevention and Policy, examined over twenty brands and found a consistent pattern: branding elements are pervasive and deliberate. Logos, proprietary color combinations, and brand names appear on syringes just as they do on consumer goods. The researchers then conducted in-depth interviews with people who inject drugs across multiple sites. One participant explained, “I will only use BD. They have the best needle.” Another described a specific brand as “the sharpest, least painful.” These perceptions had little to do with technical specifications and everything to do with the logo etched onto the barrel.
That finding echoes what harm reduction workers have long observed. A syringe isn’t just a delivery device; it’s a tool bound up with identity, trust, and experience. When users develop that kind of brand loyalty, their behavior in moments of scarcity can shift quickly—and dangerously.
When Brand Preference Turns Risky
If a person believes only one brand works well, they might stretch behaviors in risky ways when that brand is unavailable. The study documented cases where people reused a single syringe for multiple injections, or shared a syringe with someone who had the “good” kind, simply because the exchange site had run out of the preferred brand. In a landscape where a clean needle is one of the simplest and most effective barriers against HIV and hepatitis C, a logo can override that logic. The researchers heard stories of people holding onto a syringe for an entire day, or even passing it to a friend, because it bore the mark they trusted.
This isn’t just a matter of personal choice; it’s a structural vulnerability. Supply chains at harm reduction programs often run lean, and stocking multiple brands to satisfy varied preferences strains budgets that are already thin. When a trusted brand is out of stock, the health system fails to meet the user where they are. The brand, in effect, becomes a gatekeeper.
Harm Reduction’s Brand Dilemma
Programs on the ground have been wrestling with this for years. Some try to carry a broad mix, but that’s expensive and logistically complex. Others have shifted entirely to unbranded, generic syringes—only to face fierce pushback. Users often interpret the lack of branding as a sign of low quality. “I’ve had people literally walk away because we didn’t have the blue one,” one worker told the researchers. That refusal can mean a missed opportunity not just for safe injecting equipment, but for linkage to overdose prevention, wound care, and other services.
Groups like the Harm Reduction Coalition have started tracking brand preferences because they see it as a crucial factor in uptake. As Filter reported when the study appeared, the implications stretch beyond individual behavior to how public health systems purchase and distribute supplies. A simple switch to unbranded products, however well-intentioned, can backfire if it erodes trust. The paradox is that the very absence of branding becomes a mark of distrust.
A Regulatory Vacuum
Policy attention on syringe branding is essentially nonexistent. Regulators like the FDA set standards for sterility, needle gauge, and labeling, but nothing governs the logos and colors stamped onto a product that will be used by millions of people injecting drugs. The World Health Organization’s guidance on harm reduction recommends providing a range of needle and syringe programs, yet it doesn’t address branding—a gap the study’s authors argue needs urgent filling.
Some European cities have begun experimenting with solutions. Pilot programs negotiate directly with manufacturers for high-quality but unbranded syringes, packaging them with clear quality-assurance markings from the health authority rather than the company. Early results suggest that when the source becomes the trusted brand, the logo matters less. Other ideas include warning labels about sharing, similar to those on cigarette packs, though that raises complex questions about stigma and messaging.
For now, the research leaves us with a straightforward message: if public health is serious about stopping blood-borne diseases among people who inject drugs, it can’t ignore the visual language of the tools themselves. Next time you’re near a syringe exchange—whether as a volunteer, a policymaker, or a curious neighbor—ask the staff what brands they carry, and why. The answer might reveal more about the people they serve than any intake form ever could.
Photo by Michael Heise on Unsplash
